Clik here to view.
BeiGene Announces Expansion of Coverage on China’s National Reimbursement...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List...
View ArticleClik here to view.
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
Kaneka Eurogentec社 mRNAのGMP製造能力を増強
東京 （ビジネスワイヤ） — 株式会社カネカ（本社：東京都港区、社長：田中 稔）はグループ会社Kaneka Eurogentec社（本社：ベルギー王国リエージュ州、社長：Lieven...
View ArticleClik here to view.
Kaneka expands GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A.
TOKYO Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A....
View ArticleClik here to view.
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono...
CAMBRIDGE, Mass. & MONTREAL Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has...
View ArticleClik here to view.
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products...
View ArticleClik here to view.
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
Kaneka扩张Kaneka Eurogentec S.A.旗下mRNA产品的GMP生产能力
东京 (美国商业资讯)–Kaneka Corporation（总部：东京都港区；总裁：Minoru Tanaka）(TOKYO:4118)决定在其全资拥有的欧洲地区集团公司Kaneka Eurogentec S.A.（总部：比利时列日；总裁：Lieven...
View ArticleClik here to view.
Dr. Reddy’s successfully completes full set of clinical studies of its...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that it...
View ArticleClik here to view.
MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited...
NEW YORK MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary, unaudited financial results for the...
View ArticleClik here to view.
Genexine Receives Fast Track Designation from Korean Health Authority (MFDS)...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and...
View ArticleClik here to view.
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients...
CORALVILLE, Iowa Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing...
View ArticleClik here to view.
MEDIROM Healthcare Technologies Inc. Announces Up to JPY 50 Million Stock...
NEW YORK MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that COZY LLC (“COZY”), a company owned and...
View ArticleClik here to view.
武田薬品がハチメッドのVEGFR1/2/3高選択性の経口チロシンキナーゼ阻害薬フルキンチニブの全世界（中国を除く）を対象とした独占的ライセンス権を取得へ
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 武田薬品（TSE:4502/NYSE:TAK）は本日、ハチメッド・チャイナ・リミテッド（Nasdaq/AIM: HCM、HKEX: 13）およびその子会社ハチメッド・リミテッドと、中国本土、香港、マカオを除く地域でのフルキンチニブのさらなる開発・商業化に向けて、独占的ライセンス契約を締結したと発表しました。...
View ArticleClik here to view.
研究者らがMasimo Root®の先進的なマルチモーダルモニタリング機能の力を活用し、異なるの換気戦略が胸腔鏡手術中の脳酸素化に与える影響を研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、Journal of Anesthesia & Intensive Care Medicineに掲載された前向き単盲検ランダム化対照試験の結果を発表しました。試験では、エジプトのタンタにあるタンタ大学のMona Mohamed...
View ArticleClik here to view.
KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple...
LEXINGTON, Mass. KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics...
View ArticleClik here to view.
Crown BioscienceがIndivumed GmbHのサービス事業を買収し、バイオバンクをサポートすることに合意
米国 サンディエゴ、ドイツ ハンブルグ （ビジネスワイヤ） — 世界的な医薬品開発業務受託機関（CRO）でJSRライフサイエンス社のCrown Bioscienceは、Indivumed...
View ArticleClik here to view.
冠科生物即将收购Indivumed服务板块及其生物样本库
美国圣地亚哥、德国汉堡 冠科生物——一个全球合同研究组织、JSR生命科学的旗下子公司，宣布其已签订合约收购Indivumed GmbH的IndivuServ业务板块。双方于2022年12月29日敲定了股权购买协议，根据特有结算调整，交易将于2023年四月完成。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
SAN DIEGO & HAMBURG, Germany Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the...
View Article